Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322289 | 0.85 | MEN1 (0.60) | MEN1KMT2AALOX15LMNATSHR | |
| SCHEMBL1374503 | 0.82 | MEN1 (0.52) | MEN1KMT2AALOX15LMNATSHR | |
| SCHEMBL424448 | 0.79 | MEN1 (0.51) | MEN1KMT2AALOX15LMNATSHR | |
| SCHEMBL13758955 | 0.79 | CYP3A4 (0.51) | MEN1KMT2AALOX15TSHRSMN1; SMN2 | |
| SCHEMBL3323222 | 0.77 | MAPT (0.60) | MEN1KMT2AALOX15LMNANPSR1 | |
| SCHEMBL1377779 | 0.76 | KMT2A (0.52) | MEN1KMT2AALOX15LMNAGAA | |
| SCHEMBL13758969 | 0.76 | FOXO1 (0.49) | MEN1KMT2AALOX15LMNATSHR | |
| SCHEMBL912585 | 0.74 | ALDH1A1 (0.50) | MEN1KMT2ALMNATSHRGAA | |
| SCHEMBL1373842 | 0.70 | MEN1 (0.52) | MEN1KMT2AALOX15LMNATSHR | |
| SCHEMBL4402279 | 0.69 | MEN1 (0.51) | MEN1KMT2AALOX15GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7045517-B2 | Used to treat disorders associated with interleukin-12 overproduction; antiarthritic, antidiabetics; treating sepsis, Crohn's disease, multiple sclerosis, or psoriasis | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060069090-A1 | Triazine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-03-30 | — | — | US | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040053926-A1 | Triazine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-6680315-B2 | COMPOUNDS THAT DOWN-REGULATE INTERLEUKIN-12 PRODUCTION USED FOR TREATING INFLAMMATORY DISEASES: RHEUMATOID ARTHRITIS, SEPSIS, CHROHN'S DISEASE, MULTIPLE SCLEROSIS, PSORIASIS OR INSULIN-DEPENDENT DIABETES | SYNTA PHARMACEUTICALS CORP. | 2004-01-20 | — | — | US | disclosed |
| US-20020082259-A1 | Triazine compounds | SYNTA PHARMACEUTICALS CORP. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | MEN1 149/4885KMT2A 2431/4885ALOX15 3088/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | MEN1 149/4885KMT2A 2431/4885ALOX15 3088/4885 |
| US-20020082259-A1 | Triazine compounds | CBR1, CBR3, SCO2 | MEN1 4394/4885KMT2A 2009/4885ALOX15 1387/4885 |
| US-20040053926-A1 | Triazine compounds | CBR1, CBR3, SCO2 | MEN1 4394/4885KMT2A 2009/4885ALOX15 1387/4885 |
| US-20060069090-A1 | Triazine compounds | SCO2, NOXO1, NR2C2 | MEN1 4567/4885KMT2A 3110/4885ALOX15 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.